Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. (Q54288492)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. |
scientific article |
Statements
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. (English)
1 reference
Bernard Zinman
1 reference
J Hans DeVries
1 reference
Bruce Bode
1 reference
David Russell-Jones
1 reference
Lawrence A Leiter
1 reference
Alan Moses
1 reference
Thue Johansen
1 reference
Robert Ratner
1 reference
NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators
1 reference
9 July 2013
1 reference
1
1 reference
123-131
1 reference
2
1 reference
Identifiers
1 reference